Yanxia Shi

16PUBLICATIONS
16CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Nov 07, 2025
Chidamide (a Histone Deacetylase Inhibitor) Plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Phase Ib Trial.

Qi-Xiang Rong, Mei-Ting Chen, Wei Yang

|Sep 12, 2025
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study.

Qingru Zhou, Yuanyuan Li, Ni He

|Jul 01, 2025
Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.

Cong Xue, Qianyi Liao, Riqing Huang

|Apr 08, 2025
Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Meiting Chen, Riqing Huang, Qixiang Rong

|Mar 10, 2025
PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First-Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study.

Riqing Huang, Haifeng Li, Shuo Li

|Jan 13, 2025
Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer.

Riqing Huang, Anqi Hu, Qixiang Rong

Pageof 3

Frequent Collaborators

6 joint publications

Meiting Chen

4 joint publications

Xin An

3 joint publications

Cong Xue

3 joint publications

Shusen Wang